Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06238700

Study on Allopregnanolone and Depression in Women Across the Menopause Transition

Targeting Allopregnanolone to Probe Behavioral and Neurobiological Mechanisms That Underlie Depression in Women Across the Menopause Transition

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Brigham and Women's Hospital · Academic / Other
Sex
Female
Age
40 Years – 60 Years
Healthy volunteers
Not accepted

Summary

This study aims to identify how enhanced allopregnanolone activity (via pregnenolone) affects behavior and neurobiology that may underlie perimenopausal depression.

Detailed description

Midlife women are burdened with depression risk that is at least partly attributed to changing reproductive steroid dynamics across a prolonged reproductive transition. We hypothesize that declining endogenous allopregnanolone (ALLO) levels across the menopause transition underlies perimenopausal depression. This mechanistic trial aims to amplify the contrast between lower endogenous ALLO levels in perimenopausal women and higher levels induced by pregnenolone. This will be achieved by using the over-the-counter dietary supplement, pregnenolone, in a randomized, double-blind, parallel-arm, placebo-controlled trial. By manipulating ALLO levels together with key measurement of depression domains, this study harnesses the endocrine biology of perimenopause to explicate behavioral and neurobiological mechanisms underlying depression in women across the menopause transition.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTpregnenolonePregnenolone is an endogenous steroid available in the US and elsewhere as an orally administered over-the-counter supplement.
OTHERplaceboPlacebo pills are identical-appearing capsules containing cellulose

Timeline

Start date
2024-05-14
Primary completion
2027-07-31
Completion
2027-08-31
First posted
2024-02-02
Last updated
2025-12-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06238700. Inclusion in this directory is not an endorsement.